Skip to main content

Nasal Pandemic Influenza Vaccine

Objective

The project is being undertaken in response to the need to develop an effective, user friendly, heat stable vaccine to control the highly pathogenic form of avian influenza virus (H5 and H7 subtypes) which has the potential to cause another global influenza pandemic. The overall objective of this programme is to develop a nasal avian influenza vaccine using ChiSys® (chitosan), which is a chitosan-based technology of Archimedes Development Ltd.. Chitosan has already been tested with several nasally delivered antigens pre-clinically and clinically with excellent results. The most effective way of controlling a pandemic flu would be via the nasal route as this route is advantaged to generate both systemic and mucosal antibodies; the latter allowing virus control at its point of entry. In comparison the currently used injection route cannot achieve the mucosal response. Intranasal vaccination has further advantages: avoids the need for injection and safe disposal of syringes, eliminate the risk of HIV transmission through re-use or accidental contact with body fluids, have greater public compliance and well-suited to rapid mass global vaccination programmes. The scientific objectives of the project are: induce both systemic and mucosal immunity, evaluation of efficacy and toxicity in preclinical studies, evaluation of efficacy and safety profile in humans, provide a substantial level of cross-immunity against a drifted strains of H5 or H7, effective at low dose to meet the global demands from limited vaccine stockpiles, thermal stability so as to avoid refrigeration for storage and transportation and user friendly vaccine applicator. The consortium members have extensive experience in their specialist fields which would enable the success of this project. ChiSys® would be an excellent candidate for developing an intranasal pandemic influenza vaccine to provide a quantum leap in successfully combating pandemic influenza globally.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/influenza

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

ARCHIMEDES DEVELOPMENT LIMITED
Address
Albert Einstein Centre Nottingham Science And Technology Park
NG7 2TN Nottingham
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 977 621,40
Administrative Contact
Anthony Rhodes (Mr.)

Participants (7)

UNIVERSITY OF LEICESTER
United Kingdom
EU contribution
€ 97 812
Address
University Road
LE1 7RH Leicester
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marie Singer (Ms.)
Public Health England an Executive Agency of the Dept of Health
United Kingdom
EU contribution
€ 80 106
Address
Waterloo Road
SE1 8UG London
Activity type
Research Organisations
Administrative Contact
Amanda King (Ms.)
RETROSCREEN VIROLOGY LTD
United Kingdom
EU contribution
€ 1 017 929,60
Address
New Road Queen Mary Bioenterprise Innovation Centre 42
E1 2AX London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
John Oxford (Prof.)
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Ireland
EU contribution
€ 494 016
Address
College Green
2 Dublin
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Deirdre Savage (Ms.)
UNIVERSITETET I BERGEN
Norway
EU contribution
€ 504 167
Address
Museplassen 1
5020 Bergen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Inger Gjesdahl (Ms.)
UNIVERSITA DEGLI STUDI DI SIENA
Italy
EU contribution
€ 245 250
Address
Via Banchi Di Sotto 55
53100 Siena
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Silvano Focardi (Prof.)
EVICOM LTD
United Kingdom
EU contribution
€ 156 746
Address
Lyndhurst Road, Ascentia House
SL5 9ED Ascot
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alastair Knight (Dr.)